Amedisys Stock Forecast, Price & News

Amedisys' stock was trading at $170.47 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMED shares have increased by 38.2% and is now trading at $235.61.
View which stocks have been most impacted by COVID-19.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amedisys.

Amedisys is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Amedisys.

Amedisys Inc (NASDAQ:AMED) posted its earnings results on Tuesday, July, 28th. The health services provider reported $1.34 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.81 by $0.53. The health services provider earned $485.06 million during the quarter, compared to analyst estimates of $468.38 million. Amedisys had a net margin of 6.50% and a return on equity of 22.41%. The business's revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.21 earnings per share.
View Amedisys' earnings history.

Amedisys updated its FY20 earnings guidance on Tuesday, July, 28th. The company provided EPS guidance of $4.84-5.06 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.54. The company issued revenue guidance of $2.04-2.07 billion, compared to the consensus revenue estimate of $2.03 billion.

14 equities research analysts have issued 1-year price objectives for Amedisys' stock. Their forecasts range from $160.00 to $290.00. On average, they expect Amedisys' stock price to reach $239.43 in the next twelve months. This suggests a possible upside of 1.6% from the stock's current price.
View analysts' price targets for Amedisys.

Amedisys saw a decrease in short interest in September. As of September 15th, there was short interest totaling 420,900 shares, a decrease of 32.4% from the August 31st total of 623,000 shares. Based on an average trading volume of 288,800 shares, the short-interest ratio is presently 1.5 days. Currently, 1.3% of the shares of the company are sold short.
View Amedisys' Short Interest.

Some companies that are related to Amedisys include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Chemed (CHE), LHC Group (LHCG), AMN Healthcare Services (AMN), R1 RCM (RCM), CorVel (CRVL), MEDNAX (MD), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO), Intel (INTC) and Home Depot (HD).

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMED stock can currently be purchased for approximately $235.61.

Amedisys has a market capitalization of $7.65 billion and generates $1.96 billion in revenue each year. The health services provider earns $126.83 million in net income (profit) each year or $4.40 on an earnings per share basis. Amedisys employs 21,300 workers across the globe.

The official website for Amedisys is www.amedisys.com.

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]